

Supplementary table 4. Predictive value of stroke adverse outcomes according to OXLDL Levels stratified by Clopidogrel-Aspirin or Aspirin.

Outcome	Clopidogrel–Aspirin			P for trend	Aspirin			P for trend	P for interaction
	ox-LDL T1	ox-LDL T2	ox-LDL T3		ox-LDL T1	ox-LDL T2	ox-LDL T3		
Stroke									0.2344
Events,n(%)	63(2.17)	73(2.52)	76(2.62)		60(2.06)	96(3.30)	100(3.43)		
Unadjusted HR	Reference	1.14(0.81-1.60)	1.21(0.87-1.69)	0.5320	Reference	1.66(1.20-1.30)	1.72(1.25-2.36)	0.0018	
Adjusted HR*	Reference	1.12(0.78-1.60)	1.20(0.79-1.82)	0.6920	Reference	1.62(1.15-2.28)	1.69(1.13-2.53)	0.0144	
Composite vascular event									0.2422
Events,n(%)	65(2.24)	75(2.58)	78(2.69)		61(2.09)	97(3.33)	101(3.47)		
Unadjusted HR	Reference	1.14(0.82-1.58)	1.20(0.86-1.67)	0.5412	Reference	1.65(1.20-2.27)	1.70(1.24-2.34)	0.0019	
Adjusted HR*	Reference	1.10(0.78-1.57)	1.16(0.77-1.75)	0.7732	Reference	1.60(1.14-2.25)	1.67(1.12-2.50)	0.0158	
Ischemic stroke									0.1499
Events,n(%)	61(2.10)	66(2.27)	71(2.45)		59(2.03)	94(3.23)	98(3.37)		
Unadjusted HR	Reference	1.06(0.75-1.51)	1.16(0.83-1.84)	0.6797	Reference	1.65(1.20-2.91)	1.71(1.24-2.36)	0.0022	
Adjusted HR*	Reference	1.00(0.69-1.44)	1.06(0.69-1.63)	0.9424	Reference	1.61(1.14-2.28)	1.68(1.12-2.53)	0.0166	
Hemorrhagic stroke									0.9221
Events,n(%)	1(0.34)	3(0.10)	5(0.17)		1(0.34)	2(0.69)	2(0.69)		
Unadjusted HR	Reference	2.29(0.59-8.85)	1.65(0.40-6.92)	0.4825	Reference	2.05(0.19-22.56)	2.03(0.18-22.34)	0.8169	
Adjusted HR*	Reference	5.47(1.24-24.06)	7.69(1.34-44.16)	0.0505	Reference	2.58(0.16-42.45)	4.91(0.19-124.70)	0.6280	

Poor functional outcome (MRS 2-6)	0.4043							
Events,n(%)	92(3.17)	88(3.03)	98(3.38)		94(3.23)	114(3.91)	117(4.02)	
Unadjusted HR	Reference	0.93(0.69-1.27)	1.06(0.78-1.43)	0.7126	Reference	1.27(0.95-1.70)	1.29(0.97-1.72)	0.1600
Adjusted HR*	Reference	0.90(0.65-1.23)	0.98(0.66-1.45)	0.7884	Reference	1.60(0.85-1.59)	1.05(0.72-1.54)	0.6113
TIA	0.9971							
Events,n(%)	8(0.28)	7(0.24)	6(0.21)		13(0.45)	13(0.45)	11(0.38)	
Unadjusted HR	Reference	0.86(0.31-2.36)	0.74(0.26-2.14)	0.8555	Reference	1.02(0.47-2.21)	1.51(0.65-3.45)	0.8959
Adjusted HR*	Reference	1.27(0.41-3.94)	1.41(0.36-5.45)	0.8735	Reference	0.86(0.38-1.91)	1.48(0.53-4.14)	0.6140
Moderate-to-severe bleeding	0.5172							
Events,n(%)	5(0.17)	12(0.41)	8(0.28)		4(0.14)	4(0.14)	5(0.17)	
Unadjusted HR	Reference	2.36(0.83-6.69)	1.59(0.52-4.86)	0.2594	Reference	1.02(0.26-4.09)	1.27(0.34-4.72)	0.9242
Adjusted HR*	Reference	3.42(1.11-10.51)	3.03(0.79-11.53)	0.0995	Reference	2.30(0.46-11.65)	8.59(1.30-56.90)	0.0684
Any bleeding	0.4357							
Events,n(%)	22(0.76)	35(1.21)	29(1.00)		16(0.55)	18(0.62)	26(0.89)	
Unadjusted HR	Reference	1.57(0.92-2.67)	1.31(0.75-2.28)	0.2580	Reference	1.15(0.59-2.26)	1.65(0.89-3.08)	0.2406
Adjusted HR*	Reference	1.54(0.87-2.72)	1.22(0.61-2.42)	0.2901	Reference	1.40(0.68-2.88)	2.66(1.18-6.00)	0.0463
All-cause death	0.2287							
Events,n(%)	9(0.31)	11(0.38)	14(0.48)		7(0.24)	12(0.41)	6(0.21)	
Unadjusted HR	Reference	1.20(0.50-2.89)	1.54(0.67-3.57)	0.5804	Reference	1.75(0.69-4.45)	0.87(0.29-2.58)	0.2851
Adjusted HR*	Reference	1.37(0.53-3.51)	1.57(0.52-4.69)	0.7110	Reference	1.23(0.44-3.38)	0.45(0.11-1.78)	0.2009

CI, confidence interval; HR, hazard ratio; oxLDL, oxidized low-density lipoprotein; MRS, modified Rankin Scale; TIA, transient ischemic attack.

*Adjusting for age, gender, BMI, history of ischemic stroke, hypertension, diabetes mellitus, dyslipidemia, application of agents before events, qualifying event, blood pressure, and baseline LDL, HDL, CHO, TG, APOA1, and APOB levels.